SUPECT(API: Radotinib) is Asia’s 1st Chronic Myeloid Leukemia (CML) treatment which solely developed by technicians of IL-YANG Pharm. “SUPECT” had obtained its material patent in US, Canada, New Zealand, Australia, Singapore, Indonesia, Malaysia, Mexico, Vietnam, EURASIA (9 notions including Russia) and etc. Upon its approval of 1st line-treatment on October 27th, 2015, it is ready to expend its value for the Global market. Current global market of Leukemia is about 10 billion UDS, and there are only 4 2nd generation of CML treatments including “SUPECT”. In 2003, material development of “SUPECT” had been initiated, conducted multinational clinical study with world number 1 CRO on about 450 patients, and as the results “SUPECT” approved its superb ‘Efficacy and Safety’ by direct comparison with global 1st generation treatment. Furthermore, it’s Major Molecular Response (MMR), effective ratio, and initial response were also great compare to 1st generation treatment. Especially, “SUPECT” was published on SCI journals and articles and introduce as cost effective CML treatment with great efficacy, which influenced cost of other new drugs from multinational pharma company with high premium price strategy. “SUPECT” is continuously getting interests from Hematology Associations and global medical community, because of its cost effectiveness and efficacy. Lately, during “2015 BIO International Convention”, “SUPECT” was introduced as “Success case and role model of innovative new drug” and also continuously publishing on SCI journals and articles as competitive drug in global market.

“Blood”, peer-reviewed medical journal published by American Society of Hematology and “Thomson Reuters”, a major multinational mass media and information announced “SUPECT” as most famous and competitive new drug.

The globally famous medical journal, ‘Blood’ introduced “SUPECT” for its great efficacy and cost effectiveness. ‘Blood’ also mentioned “Interestingly, in South Korea, where annual prices for TKIs range from $21,000 to $28,000, market competition may have worked well, perhaps because of the approval by the Korean health authorities of radotinib (annual prices $21,500), a locally discovered and developed TKI.” ‘Blood’ strongly point out “We propose to begin the dialogue by organizing regular meetings, involving all parties concerned, to address the reasons behind high cancer drug prices and offer solutions to reduce them.”, due to continuously increasing price of “Gleevec” from Norvatis since 2001 and high prescription price of 2nd generation treatments, Tasigna(Norvatis) and Sprycel(BMS). With together, a major multinational mass media, ‘Thomson Reuters’ evaluated “SUPECT” as one of four ‘New promising cancer drug’ among all ‘Oncology’ related drug that had been approved throughout the world.

First publication on SCI international journal – Haematologica Cost-effective contrast to efficacy among TKI products/ Great efficacy proven

“SUPECT” has been published on SCI International Journal, “Haematologica” with title of “Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors”, which contains efficacy and safety of Leukemia treatment 『SUPECT』 by 12 month. In journal, introduced 『SUPECT』 as “Cost-effective contrast to its efficacy” and conclude “a cost-effective tyrosine kinase inhibitor, which can improve accessibility to the drug and increase compliance and adherence to treatment, may be necessary in emerging regions.” Moreover, the journal evaluated “Adverse events were generally transient and managed by dose reduction or interruption”, which means the safety of “SUPECT” has been proved for long-term administration.